MLYS (Mineralys Therapeutics, Inc.) Stock Market Reviews

crown

search

Read and share opinions on MLYS (Mineralys Therapeutics, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock ma

MLYS

Mineralys Therapeutics, Inc.

clarify Biotechnology

bookmark Healthcare

public United States

Sell Neutral Buy

Latest News

Mineralys Therapeutics Inc (MLYS) Q3 2025 Earnings Call Highlights: Strong Financial Position ...
Nov 11, 2025
Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Nov 10, 2025
Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025
Nov 7, 2025
Mineralys Therapeutics to Participate in Upcoming Investor Conferences
Nov 5, 2025
Mineralys Therapeutics to Announce Third Quarter 2025 Financial Results and Host Conference Call on Monday, November 10, 2025
Nov 3, 2025
Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 2 Explore-CKD Trial of Lorundrostat at American Society of Nephrology (ASN) Kidney Week 2025
Oct 21, 2025
Mineralys Therapeutics, Inc. (MLYS) Shows Positive Phase 3 HTN Results, Blood Pressure Drops in High-Risk Groups
Sep 30, 2025
Mineralys Therapeutics Completes Enrollment in Phase 2 EXPLORE-OSA Trial of Lorundrostat in Obstructive Sleep Apnea and Hypertension
Sep 30, 2025
Mineralys Therapeutics, Inc. (MLYS) is a Great Momentum Stock: Should You Buy?
Sep 29, 2025
What Makes Mineralys Therapeutics, Inc. (MLYS) a Strong Momentum Stock: Buy Now?
Sep 9, 2025
Mineralys Therapeutics Announces Closing of Upsized $287.5 Million Underwritten Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Sep 4, 2025
Mineralys (MLYS) Steals Spotlight From AstraZeneca, Reaches Fresh Peak
Sep 3, 2025
Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock
Sep 3, 2025

Reviews